Article
Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer.
Cancer immunology, immunotherapy : CII - 1 Mar 2008
Uchida Tetsuro, Horiguchi Shigetoshi, Tanaka Yuriko, Yamamoto Heizaburo, Kunii Naoki, Motohashi Shinichiro, Taniguchi Masaru, Nakayama Toshinori, Okamoto Yoshitaka
Abstract excerpt
BACKGROUND: Human Valpha24 natural killer T (NKT) cells are activated by the specific ligand, alpha-galactosylceramide (alpha-GalCer), in a CD1d-dependent manner. Potent anti-tumor activity of activated NKT cells has been previously demonstrated. METHODS: We conducted a phase I study with alpha-G...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.